Relationship between the RB1 mRNA level and the expression of phosphorylated RB protein in human breast cancers: Their relevance in cell proliferation activity and patient clinical outcome

Histology and Histopathology

Volumn 22, Issue 4-6, 2007, Pages 505-513

  Derenzini, Massimo ^a   Montanaro, L ^a   Vici, M ^a   Barbieri, S ^a   Ceccarelli, C ^b   Santini, D ^b   Taffurelli, M ^b   Martinelli, G N ^b   Trere D ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cell proliferation; Clinical outcome; Human breat cancer; RB protein phsophorylation; RB1 mRNA

Indexed keywords

KI 67 ANTIGEN; MESSENGER RNA; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; OVERALL SURVIVAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CANCER STAGING; FEMALE; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PROPORTIONAL HAZARDS MODEL; TIME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 34247524653     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Adams P.D. (2001). Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim. Biophys. Acta 1471, M123-133.
2. Altman D.G., De Stavola B.L., Love S.B. and Stepniewska K.A. (1995). Review of survival analyses published in cancer journals. Br. J. Cancer 72, 511-518.
3. Anderson J.J., Tiniakos D.G., McIntosh G.G., Autzen P., Henry J.A., Thomas M.D., Reed J., Horne G.M., Lennard T.W., Angus B. and Horne C.H. (1996). Retinoblastoma protein in human breast carcinoma: immunohistochemical study using a new monoclonal antibody effective on routinely processed tissues. J. Pathol. 180, 65-70.
4. Berns E.M., de Klein A., van Putten W.L., van Staveren I.L., Bootsma A., Klijn J.G. and Foekens J.A. (1995). Association between RB-1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival. Int. J. Cancer 64, 140-145.
5. Bieche I. and Lidereau R. (2000). Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer. Mol. Caminog. 29, 151-158.
6. Caulet S., Lesty C., Raphael M., Binet J.L. and Diebold J. (1991). Comparative quantitative study of Ki-67 antibody staining in 78 B and T cell malignant lymphoma (ML) using two image analyser systems. Anal. Quant. Cytol. Histol. 13, 279-287.
7. Ceccarelli C., Santini D., Chieco P., Taffurelli M., Gamberini M., Pileri S.A. and Marrano D. (1998). Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile. J. Clin. Pathol. 51, 818-824.
8. Classon M. and Harlow E. (2002). The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2, 910-917.
9. Cordon-Cardo C. (1995). Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am. J. Pathol. 147, 545-560.
10. Cox D.R. (1972). Regression models and life-tables. J. R. Stat. Soc. B 34, 87-220.
11. Derenzini M., Ceccarelli C., Santini D., Taffurelli M. and Treré D. (2004). The prognostic value of the AgNOR parameter in human breast cancer depends on the ppRB and p53 status. J. Clin. Pathol. 57, 755-761.
12. Elston C.W. and Ellis I.O. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19, 403-410.
13. Faccioli S., Chieco P., Gramantieri L., Stecca B.A. and Bolondi L. (1996). Cytometric measurement of cell proliferation in echo-guided biopsies from focal lesions of the liver. Mod. Pathol. 1996 9, 120-125.
14. Geradts J., Wilson P.A. (1996). High frequency of aberrant p161NK4A expression in human breast cancer. Am. J. Pathol. 149, 15-20.
15. Gillett C.E., Lee A.H., Millis R.R. and Barnes D.M. (1998). Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J. Pathol. 184, 396-400.
16. Gillett C.E., Smith P., Peters G., Lu X. and Barnes D.M. (1999). Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma. J. Pathol. 187, 200-206.
17. Harbour J.W. and Dean D.C. (2000). The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 14, 2393-2409.
18. Jares P., Rey M.J., Fernandez P.L., Campo E., Nadal A., Munoz M., Mallofre C., Muntane J., Nayach I., Estape J. and Cardesa A. (1997). Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status. J. Pathol. 182, 160-166.
19. Kobayashi M., Yamauchi Y. and Tanaka A. (1998). Stable expression of antisense Rb-1 RNA inhibits terminal differentiation of mouse myoblast C2 cells. Exp. Cell. Res. 239: 40-49.
20. Loden M., Nielsen N.H., Roos G., Emdin S.O. and Landberg G. (1999). Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene 18,2557-2566.
21. Nielsen N.H., Loden M., Cajander J., Emdin S.O. and Landberg G. (1999). G1-S transition defects occur in most breast cancers and predict outcome. Breast Cancer Res. Treat. 56, 105-112.
22. Pardee A.B. (1989), G1 events and regulation of cell proliferation. Science 246, 603-608.
23. Roesch A., Becker B., Meyer S., Hafner C., Wild P.J., Landthaler M. and Vogt T. (2000). Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma. Mod. Pathol. 18, 565-572.
24. Scholzen T. and Gerdes J. (2000). The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 182, 311-322.
25. Semczuk A., Marzec B., Roessner A., Jakowicki JA., Wojcierowski J. and Schneider-Stock R. (2002). Loss of heterozygosity of the retinoblastoma gene is correlated with the altered ppRB expression in human endometrial cancer. Virchows Arch. 441, 577-583.
26. Sherr C.J. and McCormick F. (2002). The RB and p53 pathways in cancer. Cancer Cell 2, 103-112.
27. Sherr C.J. and Roberts J.M, (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1502.
28. Sutherland R.L. and Musgrove E.A. (2004) Cyclins and breast cancer. J. Mammary Gland. Biol. Neoplasia 9, 95-104.
29. Treré D., Ceccarelli C., Migaldi M., Santini D., Taffurelli M., Tosti E, Chieco P. and Derenzini M. (2006). Cell proliferation in breast cancer: a major determinant of clinical outcome in node-positive, but not in node-negative patients. Applied Immunohistochem. Mol. Morphol. 14, 314-323.
30. Wakasugi E., Kobayashi T., Tamaki Y., Nakano Y., Ito Y., Miyashiro I., Komoike Y., Miyazaki M., Takeda T., Monden T. and Monden M. (1997). Analysis of phosphorylation of ppRB and its regulatory proteins in breast cancer. J. Clin. Pathol. 50, 407-412.
31. Xing E.P., Yang G.Y., Wang L.D., Shi S.T. and Yang C.S. (1999). Loss of heterozygosity of the Rb gene correlates with ppRB protein expression and associates with p53 alteration in human esophageal cancer. Clin. Cancer Res. 5, 1231-1240.